Labcorp Holdings Inc.
One of the world's largest medical testing companies, Labcorp runs thousands of patient service centers and supports drug development trials for biopharma clients around the globe, offering everything from routine blood work to oncology and prenatal screening. It began in 1969, when three brothers—the Powells—started testing specimens in the former laundry room of a North Carolina hospital; that lab merged with National Health Laboratories in 1995 to create today's company.
Granted 254.3K · Sold 49.7K
Granted 163.9K · Sold 118.3K
Granted 53.2K · Bought 86.35 · Sold 3.5K
Granted 27.2K · Sold 12.1K
Granted 2.5K
Granted 59.7K · Sold 30.0K
Granted 4.3K · Bought 3.5K
Granted 4.3K
Granted 24.6K · Sold 12.3K
Granted 4.3K · Sold 17.0K
Granted 2.5K · Sold 572
Granted 23.6K · Sold 8.6K
Granted 2.3K
Granted 3.4K · Sold 3.5K
Granted 3.9K · Sold 500
Granted 36.9K · Sold 25.1K
Granted 4.3K
Granted 4.6K
Granted 7.7K
Granted 8.7K
Granted 3.4K
Granted 4.1K
Granted 2.2K · Sold 762
Granted 3.2K · Sold 1.1K
Granted 4.3K · Sold 7.0K
Granted 3.2K
Granted 2.6K
Granted 16.9K · Sold 11.1K
Granted 2.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schechter Adam HPresident & CEO, Director · 48 transactions | +850% | 107.2K | 254.3K | — | 49.7K |
| Eisenberg Glenn AExecutive Vice President · 61 transactions | +1.3% | 41.5Kas of Mar 2025 | 163.9K | — | 118.3K |
| Caveney Brian JEVP, Pres of ED, CMO & CSO · 58 transactions | +301.9% | 36.5K | 53.2K | 86.35 | 3.5K |
| Berberian LanceEVP, Special Advisor, Strategy · 36 transactions | +41% | 20.0Kas of Mar 2025 | 27.2K | — | 12.1K |
| Belingard Jean-LucDirector · 6 transactions | -2.1% | 17.8Kas of Feb 2024 | 2.5K | — | — |
| Schroeder Mark SEVP, Pres Diagnostics & COO · 69 transactions | +215.1% | 15.8K | 59.7K | — | 30.0K |
| Neupert Peter MDirector · 8 transactions | +25.5% | 13.8K | 4.3K | 3.5K | — |
| Kong GarhengDirector · 5 transactions | +45.6% | 13.7K | 4.3K | — | — |
| Kirchgraber Paul RCEO, Covance Drug Development · 24 transactions | +65% | 12.9Kas of May 2023 | 24.6K | — | 12.3K |
| Anderson Kerrii BDirector · 20 transactions | — | 9.9K | 4.3K | — | 17.0K |
| Williams R SandersDirector · 4 transactions | +30.3% | 8.1Kas of Feb 2024 | 2.5K | — | 572 |
| Summy Amy B.EVP, Chief Marketing Officer · 45 transactions | +2862.2% | 7.9K | 23.6K | — | 8.6K |
| Vaughn Bryan TEVP, Diagnostics · 8 transactions | — | 6.7K | 2.3K | — | — |
| Gilliland Dwight GaryDirector · 10 transactions | -1.4% | 6.7Kas of Jul 2025 | 3.4K | — | 3.5K |
| DiVincenzo Jonathan P.EVP, Pres, Central Labs & Intl · 13 transactions | — | 6.4Kas of Mar 2024 | 3.9K | — | 500 |
| van der Vaart Sandra DEVP, Corporate Affairs · 62 transactions | -35.9% | 6.2K | 36.9K | — | 25.1K |
| Davis Jeffrey A.Director · 5 transactions | +371.1% | 5.5K | 4.3K | — | — |
| Seltz Judith CEVP, CHRO · 12 transactions | +484.3% | 5.3Kas of Mar 2023 | 4.6K | — | — |
| Bailey Megan D.EVP, Pres, Central Labs & Intl · 28 transactions | — | 5.3K | 7.7K | — | — |
| Graham Anita ZEVP, CHRO · 14 transactions | — | 5.2K | 8.7K | — | — |
| Oyegunwa AkinboladeEVP, CIO & CTO · 18 transactions | — | 5.1K | 3.4K | — | — |
| Wengel Kathryn EDirector · 5 transactions | — | 4.1K | 4.1K | — | — |
| Kyle Kathryn WEVP, Chief Legal Officer · 9 transactions | — | 3.8K | 2.2K | — | 762 |
| Meltzer Jonathan CEVP, Operations · 12 transactions | — | 3.6K | 3.2K | — | 1.1K |
| Parham Richelle PDirector · 6 transactions | -44.6% | 3.4K | 4.3K | — | 7.0K |
| Kliphouse Kirsten MarieDirector · 4 transactions | — | 3.2K | 3.2K | — | — |
| Rothman PaulDirector · 3 transactions | — | 2.6K | 2.6K | — | — |
| Wilkinson Peter JSVP, Chief Accounting Officer · 62 transactions | +83.2% | 1.9K | 16.9K | — | 11.1K |
| Wang Julia AijunChief Financial Officer, EVP · 6 transactions | — | 1.8K | 2.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -297.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.